Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Genetic Variant Screening of DNA Repair Genes in Myelodysplastic Syndrome Identifies a Novel Mutation in the XRCC2 Gene

J. Valka, J. Vesela, H. Votavova, M. Dostalova-Merkerova, Z. Urbanova, A. Jonasova, J. Cermak, M. Belickova,

. 2019 ; 42 (5) : 263-268. [pub] 20190312

Language English Country Netherlands

Document type Journal Article

Grant support
NV16-33485A MZ0 CEP Register
NV16-33485A MZ0 CEP Register

BACKGROUND: We aimed to detect single nucleotide polymorphisms (SNPs) and mutations in DNA repair genes and their possible association with myelodysplastic syndrome (MDS). METHODS: Targeted enrichment resequencing of 84 DNA repair genes was initially performed on a screening cohort of MDS patients. Real-time polymerase chain reaction was used for genotyping selected SNPs in the validation cohort of patients. RESULTS: A heterozygous frameshift mutation in the XRCC2 gene was identified. It leads to the formation of a truncated non-functional protein and decreased XRCC2 expression level. Decreased expression levels of all DNA repair genes functionally connected with mutated XRCC2 were also present. Moreover, a synonymous substitution in the PRKDC gene and 2 missense mutations in the SMUG1 and XRCC1 genes were also found. In the screening cohort, 6 candidate SNPs were associated with the tendency to develop MDS: rs4135113 (TDG, p = 0.03), rs12917 (MGMT, p = 0.003), rs2230641 (CCNH, p = 0.01), rs2228529 and rs2228526 (ERCC6, p = 0.04 and p = 0.03), and rs1799977 (MLH1, p = 0.04). In the validation cohort, only a polymorphism in MLH1 was significantly associated with development of MDS in patients with poor cytogenetics (p = 0.0004). CONCLUSION: Our study demonstrates that genetic variants are present in DNA repair genes of MDS patients and may be associated with susceptibility to MDS.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19034723
003      
CZ-PrNML
005      
20191105103945.0
007      
ta
008      
191007s2019 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000497209 $2 doi
035    __
$a (PubMed)30861523
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Valka, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czechia, jan.valka@uhkt.cz. Charles University,1st Faculty of Medicine, Prague, Czechia, jan.valka@uhkt.cz.
245    10
$a Genetic Variant Screening of DNA Repair Genes in Myelodysplastic Syndrome Identifies a Novel Mutation in the XRCC2 Gene / $c J. Valka, J. Vesela, H. Votavova, M. Dostalova-Merkerova, Z. Urbanova, A. Jonasova, J. Cermak, M. Belickova,
520    9_
$a BACKGROUND: We aimed to detect single nucleotide polymorphisms (SNPs) and mutations in DNA repair genes and their possible association with myelodysplastic syndrome (MDS). METHODS: Targeted enrichment resequencing of 84 DNA repair genes was initially performed on a screening cohort of MDS patients. Real-time polymerase chain reaction was used for genotyping selected SNPs in the validation cohort of patients. RESULTS: A heterozygous frameshift mutation in the XRCC2 gene was identified. It leads to the formation of a truncated non-functional protein and decreased XRCC2 expression level. Decreased expression levels of all DNA repair genes functionally connected with mutated XRCC2 were also present. Moreover, a synonymous substitution in the PRKDC gene and 2 missense mutations in the SMUG1 and XRCC1 genes were also found. In the screening cohort, 6 candidate SNPs were associated with the tendency to develop MDS: rs4135113 (TDG, p = 0.03), rs12917 (MGMT, p = 0.003), rs2230641 (CCNH, p = 0.01), rs2228529 and rs2228526 (ERCC6, p = 0.04 and p = 0.03), and rs1799977 (MLH1, p = 0.04). In the validation cohort, only a polymorphism in MLH1 was significantly associated with development of MDS in patients with poor cytogenetics (p = 0.0004). CONCLUSION: Our study demonstrates that genetic variants are present in DNA repair genes of MDS patients and may be associated with susceptibility to MDS.
650    _2
$a mutační analýza DNA $7 D004252
650    12
$a oprava DNA $7 D004260
650    _2
$a proteinkinasa aktivovaná DNA $x genetika $7 D051747
650    _2
$a DNA vazebné proteiny $x genetika $7 D004268
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a MutL homolog 1 $x genetika $7 D000070957
650    12
$a mutace $7 D009154
650    _2
$a myelodysplastické syndromy $x enzymologie $x genetika $x metabolismus $7 D009190
650    _2
$a jaderné proteiny $x genetika $7 D009687
650    _2
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a uracil-DNA-glykosidasa $x genetika $7 D051981
650    _2
$a protein XRCC1 $x genetika $7 D000076105
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vesela, Jitka $u Institute of Hematology and Blood Transfusion, Prague, Czechia.
700    1_
$a Votavova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czechia.
700    1_
$a Dostalova-Merkerova, Michaela $u Institute of Hematology and Blood Transfusion, Prague, Czechia.
700    1_
$a Urbanova, Zuzana $u Institute of Hematology and Blood Transfusion, Prague, Czechia. Charles University,1st Faculty of Medicine, Prague, Czechia.
700    1_
$a Jonasova, Anna $u First Internal Clinic - Clinic of Hematology, General University Hospital, Prague, Czechia.
700    1_
$a Cermak, Jaroslav $u Institute of Hematology and Blood Transfusion, Prague, Czechia.
700    1_
$a Belickova, Monika $u Institute of Hematology and Blood Transfusion, Prague, Czechia.
773    0_
$w MED00200658 $t Oncology research and treatment $x 2296-5262 $g Roč. 42, č. 5 (2019), s. 263-268
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30861523 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191105104214 $b ABA008
999    __
$a ok $b bmc $g 1451383 $s 1073273
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 42 $c 5 $d 263-268 $e 20190312 $i 2296-5262 $m Oncology research and treatment $n Oncol Res Treat $x MED00200658
GRA    __
$a NV16-31689A $a NV16-33485A $p MZ0 $p MZ0
GRA    __
$a NV16-31689A $a NV16-33485A $p MZ0 $p MZ0
LZP    __
$a Pubmed-20191007

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...